CHE — Chemed Corp

Is CHE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Overbought As of November 17, 2026

Chemed Corp (CHE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $546.75. The rating moved from Neutral to Overbought on November 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Chemed Corp (CHE) combines a defensive hospice franchise with a complementary home services business, producing consistent cash flow and margin resilience. The company benefits from demographic-driven demand and a history of disciplined capital deployment, including M&A and buybacks, which support EPS durability. Near-term catalysts include continued organic hospice admissions growth, efficiency improvements, and selective tuck‑in acquisitions that can expand specialty service footprints. Key headwinds center on heightened CMS program integrity initiatives that raise audit and compliance risk, potential reimbursement adjustments, and operational pressure from labor inflation. Market liquidity and social sentiment are muted, and the current macro backdrop favors consolidation rather than aggressive share movement. Overall outlook is cautiously positive if management navigates regulatory changes and sustains margin expansion; downside scenarios would be driven primarily by adverse reimbursement rulings or a notable deterioration in service demand.

Key factors

  • Diversified service model: hospice (VITAS) and home services (Roto-Rooter) provide revenue diversification and countercyclical balance.
  • Strong historical cash flow generation and margin profile supporting reinvestment, M&A and share repurchases.
  • Favorable demographic tailwinds (aging population) supporting long‑term demand for hospice and home health services.
  • Pricing power and high recurring revenue mix in hospice business with predictable per‑diem reimbursement.
  • Management track record of disciplined capital allocation and operational efficiency improvements.

Risks

  • Elevated regulatory risk from recent CMS proposals and broader program integrity efforts that could increase audits, RADV adjustments or reimbursement pressure.
  • Exposure to reimbursement changes or clawbacks under Medicare/Medicare Advantage; tighter compliance increases operating overhead.
  • Labor cost inflation and staffing shortages in clinical and field service roles that could compress margins and limit growth.
  • Cyclical weakness in home services demand (Roto‑Rooter) during macro downturns could offset hospice stability.
  • Relatively high valuation versus peers increases downside if growth or earnings cadence disappoints.
  • Concentration risk: material exposure to U.S. Medicare policy and state/regional regulatory environments.

See today's live rating, score and targets

Members see the live hourly rating for CHE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.